Medical Marijuana for Alzheimer's Disease in Florida
Progressive neurodegenerative disease causing memory loss and cognitive decline.
Medically reviewed by Bruce Stratt, MD
Board-Certified Physician · OMMU Certified · Boca Raton, FL
Overview
Alzheimer's Disease is the most common form of dementia, affecting approximately 6.7 million Americans aged 65 and older. It is a progressive neurodegenerative condition characterized by worsening memory loss, confusion, disorientation, personality changes, difficulty with language and problem-solving, and ultimately the inability to carry out basic daily tasks. Alzheimer's is caused by abnormal accumulation of amyloid plaques and tau tangles in the brain, leading to neuron death and brain atrophy.
The disease progresses through stages — from mild cognitive impairment to severe dementia requiring full-time care. Current FDA-approved treatments include cholinesterase inhibitors, memantine, and newer anti-amyloid antibodies (lecanemab, donanemab), which can temporarily slow progression in some patients but do not halt the underlying disease course. Behavioral symptoms including agitation, aggression, anxiety, depression, and sleep disturbances are particularly challenging — they are the primary driver of caregiver burnout and often lead to antipsychotic use, which carries an FDA black-box warning for increased mortality in dementia patients.
Florida recognizes Alzheimer's-related symptoms as qualifying for medical marijuana under Statute 381.986. This is particularly significant given Florida's large elderly population and the growing body of clinical evidence supporting cannabinoids as a safer alternative to antipsychotics for managing behavioral symptoms of dementia.
How Medical Cannabis May Help
Clinical evidence for cannabinoids in Alzheimer's has grown substantially. A randomized, double-blind, placebo-controlled crossover trial (Herrmann et al., American Journal of Geriatric Psychiatry, 2019) tested nabilone (synthetic THC) in 39 patients with moderate-to-severe Alzheimer's and found it significantly reduced agitation on the Cohen-Mansfield Agitation Inventory (P=0.003) and overall neuropsychiatric symptoms (P=0.004). Caregiver distress also significantly improved. A larger trial — the THC-AD study (Mintzer et al., 2024) — randomized 75 Alzheimer's patients to dronabinol (5mg twice daily) or placebo. Dronabinol reduced agitation by 30% on the Pittsburgh Agitation Scale with an effect size of 0.53. Critically, 84% of participants completed the trial with no reports of delirium or seizures — a remarkable safety profile compared to antipsychotics, which carry FDA black-box warnings for increased mortality in dementia patients. A pilot study (Shelef et al., Journal of Alzheimer's Disease, 2016) also found significant reductions in agitation, irritability, and nocturnal behavior with medical cannabis oil. Beyond behavioral symptom management, preclinical research suggests cannabinoids may have neuroprotective properties relevant to Alzheimer's pathology — including reducing amyloid plaque formation, decreasing neuroinflammation via CB2 receptor activation on microglia, and reducing glutamate excitotoxicity. THC activates CB1 receptors in the hypothalamus to stimulate appetite — critical for Alzheimer's patients who refuse food during agitated states. Dr. Stratt works closely with patients and their caregivers to develop appropriate, carefully monitored treatment plans with conservative dosing that prioritizes safety.
Individual results vary. Consult with Dr. Stratt to understand how cannabis therapy may apply to your specific situation.
What to Bring to Your Appointment
Bring a valid Florida ID and neurology records confirming Alzheimer's diagnosis, cognitive assessment results, current medication list. A caregiver should accompany the patient to the evaluation.
Frequently Asked Questions
Related Articles
Patient Resources
Get Your Medical Marijuana Card for Alzheimer's Disease
Schedule your evaluation with Dr. Stratt. Same-day state registry submissions for qualifying patients.